CEL-SCI Corporation (NYSE American: CVM) — Form 10-Q Summary
Reporting period: Fiscal quarter and six months ended March 31, 2024 (the second quarter of fiscal 2024). The company is a clinical-stage biotechnology company developing Multikine for head and neck cancer and LEAPS candidates for rheumatoid arthritis. It reported no product revenue; candidates are investigational and none are approved for sale.
Financial results and position
| Metric | Six months ended March 31, 2024 | Prior comparable period |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $9.0 million | $11.5 million |
| General and administrative expense | $4.6 million | $4.4 million |
| Operating loss | $13.6 million | $15.8 million |
| Net loss | $14.0 million | $16.2 million |
| Net loss per share, basic and diluted | $0.28 | $0.38 |
| Cash used in operating activities | $9.4 million | $12.1 million |
For the three months ended March 31, 2024, operating expenses were $7.1 million and net loss was $7.2 million, versus $8.2 million and $8.3 million, respectively, a year earlier. There are no meaningful revenue or profit margins to assess because the company has not begun commercial sales.
- Liquidity: Cash and cash equivalents were $5.3 million at March 31, 2024, up from $4.1 million at September 30, 2023. Current assets were $8.5 million and current liabilities $5.1 million.
- Financing and cash flow: Net financing cash inflow was $10.6 million, chiefly from $12.7 million in common-stock proceeds, less $1.2 million of issuance costs and $0.9 million in finance-lease payments. The November 2023 and February 2024 offerings together generated approximately $11.5 million net.
- Debt and leases: The balance sheet reports $10.9 million of finance-lease obligations and $1.8 million of operating-lease obligations, including current portions. Future minimum finance-lease payments total approximately $13.1 million before imputed interest.
- Equity: Shares outstanding were 54.1 million at March 31, 2024; the filing reports 54.16 million outstanding on May 9. The six-month weighted-average share count rose to 50.2 million from 43.5 million.
Material changes and operating developments
Six-month R&D expense fell $2.5 million, or 22%, principally because Phase 3 trial expenses declined approximately $1.6 million and employee stock compensation declined approximately $0.6 million. G&A expense increased approximately $0.2 million, or 5%. For the March quarter, R&D declined 24%, while G&A increased 17%, including higher consulting costs and expense related to accelerated vesting of director options.
The company accelerated vesting of 234,332 director options in March 2024; approximately $260,000 of remaining compensation cost is to be recognized over the remaining service period. It issued 6.365 million shares in the November and February public offerings for gross proceeds of $12.73 million. After quarter-end, it extended the expiration of 1,092,470 warrants for two years and officers and directors purchased 58,000 restricted shares.
Outlook, risks and contingencies
- Going concern and funding: Management states recurring operating losses and future liquidity needs create substantial doubt about the company’s ability to continue as a going concern. It expects to require additional capital or long-term financing; fundraising may not be available timely, on acceptable terms, or at all. Failure to raise funds could require curtailing operations. The company does not expect significant revenue until licensing or regulatory approval, which could take several years.
- Multikine clinical and regulatory status: Management highlights Phase 3 subgroup analyses, including a reported five-year survival of 73% for the selected target population versus 45% for controls. However, the overall Phase 3 study did not meet its primary endpoint, and the selected population’s efficacy has not been prospectively tested. The filing describes the May 2024 FDA discussion as allowing the company to move forward with a 212-person confirmatory Registration Study in patients with no lymph-node involvement and low PD-L1 expression. This is not marketing approval; trial execution, results, funding, and any future regulatory decision remain uncertain. Management’s clinical interpretations are not established efficacy or approval.
- Trial commitments: The company estimates approximately $0.6 million in remaining direct costs for its completed Phase 3 trial and clinical study report, excluding other related costs such as manufacturing. Ergomed has provided approximately $11.9 million of its up-to-$12 million contribution through discounted clinical services, in exchange for specified milestone and royalty participation.
- Lease and liquidity exposure: A $2.3 million landlord deposit remains on the balance sheet after the company fell below a cash threshold in its San Tomas manufacturing-facility lease; the deposit is to be returned only after the minimum cash requirement is met. Finance leases include the long-term manufacturing facility lease, expiring in October 2028.
- Controls: Management concluded disclosure controls and procedures were not effective at March 31, 2024 because of material weaknesses previously reported in the 2023 Form 10-K. No material change in internal control was reported during the quarter.
Most important facts for investors to verify
- Cash runway, forthcoming financing needs and the conditions for return of the $2.3 million lease deposit.
- FDA correspondence and the precise status, design, timing, enrollment, cost and funding of the proposed 212-person confirmatory study.
- Whether the Phase 3 subgroup survival results are validated prospectively, given the failed primary endpoint and the filing’s statement that the target population has not been tested prospectively.
- Potential dilution from future equity raises, warrants, options and stock-based compensation.
- Remediation of the material weaknesses underlying ineffective disclosure controls.